Open access peer-reviewed chapter

Structural Basis and Functional Mechanism of Lipoprotein in Cholesterol Transport

Written By

Zhiwei Yang, Dongxiao Hao, Yizhuo Che, Lei Zhang and Shengli Zhang

Submitted: February 7th, 2018 Reviewed: February 27th, 2018 Published: August 8th, 2018

DOI: 10.5772/intechopen.76015

Chapter metrics overview

1,549 Chapter Downloads

View Full Metrics


Lipoprotein transports lipids in circulation and is primary driver/modulator of atherosclerosis. Highly dynamics of lipoprotein conformations are crucial to lipid transport along the cholesterol transport pathway, where high-density lipoprotein (HDL), low-density lipoprotein (LDL) and cholesteryl ester transfer protein (CETP) are major players in lipid digestion & transport and the plasma cholesterol metabolism. This chapter covered how do HDL, LDL and CETP induce the metabolisms during cholesterol transport, and summarized recent process in the spatial information of the three lipoproteins, especially the elevations of plasma HDL and LDL, and shine a light on the assembly processes of lipoprotein particles and the substrates dynamics exchanges, for an in-depth understanding on the correlation between various lipoprotein classes and cardiovascular risk.


  • lipoproteins
  • structure–function relationship
  • cholesterol transport
  • reverse cholesterol transport (RCT)
  • lipoprotein particle metabolism

1. Introduction

Cardiovascular disease (CVD), a leading cause of mortality in many developed and developing countries [1], roots in the evolvement of atherosclerosis which is associated with profound disturbances of cholesterol metabolism. To some degree, these metabolism disturbances attribute to the net movement of cholesterol among blood and peripheral tissues. For instance, cellular cholesterol uptake is increased in atherosclerosis, while cholesterol efflux is downregulated [2]. Lipoproteins (consists of apolipoproteins, phospholipid and cholesterol) play an important role in the transport of cholesterol [3]. Based on density and size, lipoproteins can be classified as ultra-low- (chylomicrons), very low- (VLDL), intermediate- (IDL), low- (LDL), and high- density lipoproteins (HDL) [4]. The last two might be the significant sections of cholesterol transport and metabolism: (1) LDL could transfer lipids into the blood vessel walls, and contribute to the atherosclerosis, which causally be associated with CVD and all-cause mortality; (2) HDL could remove the lipids and carry them back to the liver, being regarded as “good” one [5, 6]. Hence, the lipoprotein-mediated cholesterol metabolism (cholesterol transport) has aroused great attention and showed the benefit for the in-depth understanding of CVDs, as well as the prevention and treatment of CVDs.

As shown in Figure 1, the lipoprotein-mediated cholesterol metabolism can be divided into exogenous and endogenous pathways [7]. Exogenous pathway is one of crucial ways to transport cholesterol to the body tissues (chylomicrons → VLDL → IDL → LDL) [8, 9], under the co-action of lipoprotein lipase (LPL) and hepatic lipase (HL) [10, 11]. While the higher plasma LDL level might drive the process of atherosclerosis [12]. Endogenous pathway delivers cholesteryl esters back to the liver, working cooperatively in a concurrent manner with ATP-binding cassette transporter A1 (ABCA1) [13], enzyme lecithin-cholesteryl acyltransferase (LCAT) [14], as well as HDL receptors scavenger receptor B1 (SR-BI) [15] or other unidentified HDL receptor (HDLR) [16]. It is widely accepted that HDL protein particles alleviate atherosclerosis with better cardiovascular health (reverse cholesterol transport, RCT) [6, 17, 18]. Besides, cholesteryl ester transfer protein (CETP) does a heteroexchange of triglycerides and cholesteryl esters between VLDL/ LDL and HDL, with the lessen of cholesterol eliminations [19, 20]. Therefore, the functions of HDL, LDL and CETP play the important roles during the cholesterol transport (lipoprotein particle metabolism), and pharmacological inhibition of CETP is being regarded as a way to prevent CVDs [19, 20].

Figure 1.

Lipoprotein-mediated cholesterol metabolism in human body.

To best of our knowledge, there are scant reviews elaborating the structure–function relationship of lipoproteins albeit the schematic illustrating is oncoming clear. A comprehensive understanding in this regard was endeavored, and then bioavailability that is closely related with cholesterol transport was discussed. In this chapter, we will summarize the recent achievements towards the structural basis and functional mechanism of lipoproteins in cholesterol transport, mainly focusing on functions of HDL, LDL and CETP, conformation dynamics of lipoprotein particles, and substrates dynamics exchanges.


2. Structure and function of HDL

HDL, a plasma lipoprotein, plays an important role in cholesterol metabolism [21, 22, 23], with several potentially anti-atherogenic properties (remove cholesterol from macrophages) [24, 25, 26]. Knowing the assembly mechanism and spatial information is of great importance to mediate cholesterol transport. HDLs exit three main steadier state during the cholesterol transport process: lipid-free apoA-I (apoA-I, the major protein component of HDL particles), discoidal and spherical HDL, with highly heterogeneous and differences of density, size, shape, as well as composition of lipid and protein.

2.1. Lipid-free apoA-I

Structure of full-length lipid-free apoA-I (28-kD, 243 residues) at native states still remains unclear due to its high flexibility. The initial X-ray crystal structure revealed that N-terminal truncated (Δ(1–43)) lipid-free apoA-I features “horseshoe-shape” antiparallel helical dimers [27], being regarded as a vital initial model (“double-belt” model) for comprehending the structure of apoA-I on HDL subclasses (Figure 2b) [28]. Subsequent crystal organization of lipid-free Δ(1–43)apoA-I accommodated a four-helix bundle [29, 30, 31]. However, the structural information is out of step with some physical biochemical measurements, hinting the conformation dynamics of lipid-free apoA-I. The crystal structures of the N- and C-terminally truncated proteins presented antiparallel helical dimers, with inherent properties (e.g., 5/5 repeat register, Figure 2b and c) in the lipid-bound and intermediate states [27, 32]. Amphipathic α-helix enables apoA-I to stabilize all HDL subclasses via the conformation change, and N-terminal two thirds constitute a dynamic, four-helix bundle, and the helical segments unfold and refold in seconds. While the C-terminal third, an intrinsically disordered domain, mediates initial binding to phospholipid surfaces. These structural motifs are important for the remodeling of apoA-I during the formation of various HDL particles. Nowadays, there remains some confusions for the structure of full length free apoA-I, especially the dynamic conformations in solutions. The dynamic helical structure is unfolding and refolding in seconds, and the helices bundle at the N-terminal of apoA-I is far more stable than could be achieved in isolation, with mutually stabilizing interactions [33, 34]. The highly dynamic apoA-I molecules are capable of adopting an array of conformations through remodeling HDL that is crucial to lipid transport during the RCT process. Further studies show that mutations in apoA-I induce varied types of dyslipidemias [35].

Figure 2.

Three structures of lipid-free apoA-I: (a) full-length lipid-free apoA-I, [36] (b) N-terminal truncated Δ(1–43) apoA-I dimer, [27] and (c) C-terminal truncated Δ[185–243] apoA-I dimer [32].

2.2. Discoidal HDL

Human plasma HDL is high heterogeneous, and exists as a short-lived heterogeneous substrate for LCAT in human plasma. Hence, reconstituted HDL particle (rHDL) is a powerful in vivo model system to study its structure and function, with most of the properties of native lipoprotein complexes (e.g., LCAT activation, lipid transfer, and receptor binding) [37, 38, 39]. Based on the crystal structure of Δ(1–43)apoA-I, [27] the original double-belt model features two antiparallel monomers, where each helix 5 segments directly oppose each other [40, 41], and the closely contact involved hydrophobic face of amphipathic α-helix with the fatty acid acyl chains [42]. In refined “looped belt” model, N- and C-terminal 40–50 residues doubled back as the “belt and buckle” [43], and residues 134–145 were coincide with a looping region, resulting in partial opening of the parallel belts. It is consistent with the accession between LCAT and the cholesterol and phospholipid acyl chains [44], With the aid of mass spectrometry (MS) and rHDL, lipid-free and lipid-bound apoA-I structures were solved at 104 Å resolution, and resulted in a “solar flares” model, where C-terminal of both apoA-I molecules interacted with each other, and 159–178 loop might be the LCAT binding site, with reduced deuterium exchange [45, 46], Different from normal discoidal shape, double superhelix (DSH) apoA-I model [47] has an open helical shape, with the similar interface interaction between two apoA-I molecules (5/5 double-belt). While, the DSH model is not stable, and could rapidly collapse to a disc-shaped structure during the molecular dynamics (MD) simulations [48].

In according to the rapid growth of transmission electron microscopy (EM) technique, the directly imaging particle’s structure can be performed on individual particles, in order to preferably investigate lipoprotein structures. Negative stain EM combined with cryo-EM tomography have been applied to uncover the discoidal shape of apoA-I/HDL particles (both plasma HDL and 7.8, 8.4, 9.6 nm of rHDLs) [49, 50]. In these rHDL particles, the double belt was formed in an antiparallel fashion, with a gross “right-to-right” rotation of the helices after lipidation. The nonhelical regions in lipid-free apoA-I (residues 45–53, 66–69, 116–146, and 179–236) change conformation from random coil to α-helix, to adjust a hydrophobic interior [34, 46]. Above descriptions were further confirmed by the structures of reconstituted discoidal HDL particles via nuclear magnetic resonance (NMR), electron paramagnetic resonance (EPR) and transmission electron microscopy (TEM) methods [51]. Based on the structures of lipid-free and lipid-bound apoA-I, we can speculate that the monomeric apoA-I forms a helix bundle in which the C-terminal domain binds the lipid to form a helical structure (Figure 3). Discoidal HDL are stabilized by two apoA-I molecules wrapped around the edge of the disc in an antiparallel, double-belt arrangement so that the hydrophobic PL acyl chains are protected from exposure to water [52]. These apoA-I molecules are in a highly dynamic state and adapt to discs of different sizes by certain segments forming loops that detach reversibly from the particle surface.

Figure 3.

The monomer open conformation transfer to dimer conformation of apoA-I (intermediate state) and final HDL state in solution regulated by the H5 region.

2.3. Spherical HDL

Due to the complexity of spherical HDL particles in human plasma, the spherical HDL structures are rarely known compared with lipid-free apoA-I and discoidal HDL. Recent developments in native and reconstituted spherical HDL supported a trefoil model, using by the elegant chemical cross-linking and mass spectrometry [53]. In this model, half of each apoA-I molecule in the double-belt arrangement is bent 60° out of the plane of the particle, suggesting the hinging of the Δ(1–43)apoA-I molecule is occur near residues 133 and 233 [53] which is different from the hinging of the full-length protein conformation, meanwhile, trefoil model is assumed to occur near residues 65 and 185 [54]. Determined by small angle neutron scattering method, the helical dimer with a hairpin (HdHp) model was proposed, associated with the intramolecular interactions within the hairpined apoA-I [55].

The first LpA-I HDL model at molecular level was proposed, with only apoA-I fractions isolated from human plasma [56]. These isolated human plasma HDL particles range in diameter from 8.8 to 11.2 nm and contain 3–5 apoA-I molecules. It was found that apoA-I adopts intermolecular interactions in plasma HDL which is very similar to those of the double-belt and trefoil models derived from reconstituted systems. Thus, apoA-I might adopt a common structural organization, characterized by distinct intermolecular contacts, regardless of size and shape or natural versus synthetic method of production [57]. Furthermore, circulating sHDL contains similar amount of core lipid in reconstituted sHDL and has obviously less surface lipid monolayers, indicating that the apoA-I package on native spheres is much closer than the typical recombinant particles [46]. When a HDL disc alters to a sphere (LCAT converts free cholesterol to cholesteryl ester), global apoA-I conformation does not change significantly between particles of different shapes or origins, with similar protein–protein contacts.


3. Structure and function of LDL

In normal human body, there are about 70% plasma cholesterol contained in LDLs, and the endocytosis of cholesterol-rich LDLs is mediated by LDL Receptor (LDL-R) on the surface of body cell. Hence, LDLs work as the vehicle for cholesterol transportation between liver and cells to maintain a constant cholesterol supply in human body [58, 59]. In some abnormal conditions, LDL might induce over-accumulation of cholesterol to form foam cells, resulting in the development of atherosclerosis [60]. The apo-B48 (apoprotein B48) and apo-B100 (apoprotein B100) located in surface of LDL particles tend to interact with extracellular material, which make LDL particles easy to bind with blood vessel intima [61]. The oxidation-LDL can promote lipoproteins aggregation [62, 63] and provoke inflammation by recruiting the circulating monocytes to the site followed invade the vessel wall and differentiate into macrophages, to finally produce atherosclerotic plaque [62, 64, 65, 66]. Cryo-EM combined with single particle technology and small angle scattering model reconstruction technology have been effectively applied to analyze the LDL structures, and molecular components [67]. LDLs include difference in density (~1.019–1.063), shape, size (diameter ~18–25 nm), surface charge and chemical composition [68]. A general consensus is that LDLs particles all have two compartments, an amphipathic surface phospholipid monolayer which surrounded by one single copy of apoB-100, and a hydrophobic lipid-cholesteryl esters core [69]. The structure and physical function of LDLs predominantly depend on the core-lipid composition and the conformation of the apoB-100 [70, 71].

3.1. Lipid core of LDL

Lipid core of LDL mainly consists of cholesteryl esters, some triglycerides, and some free-cholesterol. Structural changes of LDL are strikingly related to physiological temperature [72]. Lipids located in core show order arranged to a liquid-crystalline phase below the critical temperature, indicated by the results of X-ray and neutron small angle scattering technology, with the transition temperature of 15~35°C [73, 74]. Besides, the overall structure of LDL is a classical spherical particle when core structure is composed of radial cholesteryl esters arranged into a concentric spherical shell [75, 76]. However, the core-located lipids present in the liquid-crystalline state within an ellipsoidal shape particle revealed by the cryo-EM data [76, 77]. It seems reasonable to speculate that the change of temperature might indirectly change the shape of LDL particles from roughly spherical to ellipsoid [67]. Many efforts have been made to explore the structure of LDL at different temperatures, such as 4, 6 [77, 78, 79] and 37°C [80].

3.2. apoB-100 in LDL

ApoB-100 (4536 residues, ~20% of overall LDL) is the only protein component of LDL, and wrapped around the phospholipid monolayer on the surface of LDL particle, with an irregular ring shape. N- and C-terminus of apoB-100 touch each other, with the formation of a protruding globular structure at N-terminal [81]. A more generally accepted structural model of apoB-100 is “pentapartite” structure, which generated by molecular simulations. In this model, apoB-100 has five consecutive functional domains, NH2-βα1-β1-α2-β2-α3-COOH [79]. As shown in Figure 4, a new LDL reconstruction in which lipid core is revealed an organized three-layer structure by using the single particle approach, including a pair of “paddles” configurations with several long “fingers” extensions which have similar length and interval [82].

Figure 4.

Overall structure and core structure of LDL above (a) or below (b) the critical temperature.


4. Structure and function of CETP

CETP acts as a medium between lipoproteins for elevating plasma LDL-C (or VLDL-C) level and lowering HDL-C level [19]. A series of CETP inhibitors have been investigated in clinical, such as torcetrapib, dalcetrapib, evacetrapib, and anacetrapib [83, 84, 85]. However, current inhibitors represent the turbulent beginning of CETP inhibition and an increased mortality rate related to off-target effects and lack of efficacy [86, 87, 88]. Accompanying adverse effects call for a deeper exploration of the mechanism for CETP-mediated lipid transfer.

CETP is a hydrophobic transfer protein composed of 476 amino acids and reveals a so-called banana-shape (the size is 135 × 30 × 35 Å, see Figure 5) [20]. Its crystal structure includes two different β-barrel structures in N- and C- terminal respectively, and a central β-sheet with an ~60 Å-long hydrophobic central cavity, which can hold two phospholipids and two cholesterol molecules. Moreover, the two phospholipid molecules that located in two pores near the central domain expose the hydrophilic terminal to the aqueous environment and hydrophobic terminal to the hydrophobic cavity. Because of its special function to transfer cholesterol esters between HDL and LDL (or VLDL), the way of CETP interacts with lipoproteins is extremely essential. CETP shows a high binding affinity for nascent HDL and other lipoproteins to cover the lipoproteins surfaces owing to its proper curvature radius. They proposed a lipid transport mechanism, shuttle model. In this mechanism, the CETP in turn covers the surface of LDL (or VLDL) and HDL to swap LDL-cholesterol esters (or VLDL-cholesterol esters) with HDL-triglycerides. These steps are constantly recycled until the completion of the transport process, in which cholesterol esters move from LDL (or VLDL) to HDL [20]. This model based on the hydrophobic cavity of CETP and its feasibility of binding to lipoproteins, explains the mechanism of CETP-mediate lipid transfer reasonably, but there are not complex of CETP binding to lipoproteins in the cryo-EM micrographs intuitively to verify the authenticity of the model.

Figure 5.

The crystal structure of CETP (PDB: 2OBD) and three-dimensional density maps of CETP binging lipoproteins. (a) Atom figure of CETP. (b) Secondary structure of CETP. (c) Ternary complexes of HDL-CETP-LDL in cryo-EM micrographs. (d)~(f) the CETP insert into HDL, VLDL, LDL respectively in cryo-EM micrographs. (g) (color online) the tunnel model of CETP-mediated lipid transfer [89].

Zhang et al. [89] studied human recombinant CETP with cryo-EM by using an optimized negative-staining (OpNS) EM protocol [49, 90]. Applied the single-particle techniques, they obtained the 3D structure of CETP and the complexes of CETP binging to lipoproteins. In the 3D-map of complexes, they discovered the HDL-CETP binding structure which appears to be formed by N-terminal of CETP insert into HDL and the HDL-LDL (or HDL-VLDL) is formed by C-terminal of CETP insert into HDL (or LDL) (Figure 5c~f). This conclusion was later confirmed by Geraldine et al. by using large-scale atomistic molecular dynamics [91]. The measurement of the protrusion from the lipoproteins surface shows that ~48 Å of the tapered N-terminal end of CETP penetrates the HDL surface and ~25 Å of the C-terminal end of CETP penetrates the LDL surface (~20 Å of the C-terminal end of CETP penetrates the VLDL surface) reaching the lipid–rich, lipoproteins core. Furthermore, Zhang et al. proposed the tunnel model of lipid transfer mediated by CETP [89, 92, 93]. In this model, both CETP terminals finish penetrating surface sites on lipoproteins, N-terminal to HDL and C-terminal to LDL (or VLDL). Then neutral lipids, including cholesterol esters and triglycerides, transfer through the hydrophobic tunnel at the core of the CETP (Figure 5).

However, there are some discrepancies with the tunnel model mentioned above. Matthias et al. used the experiments which involve three monoclonal antibodies to demonstrate that the antibodies binding on both ends of CETP do not inhibit CETP’s function of transshipment cholesterol esters, but the antibodies on the middle does [94]. In their research they supposed that the formation of the ternary tunnel complexes is not a mechanistic prerequisite by CETP to perform its functions. Hence, the real mechanism of CETP-mediated lipid transfer still remains to be studied and verified.


5. Conclusion

In this chapter, we briefly summarized the functional mechanism and structural basis of lipoproteins (e.g., HDL, LDL and CETP) in cholesterol transport, as well as their structural dynamics during the transport process. Furthermore, the latest developments in the plasma lipoprotein (HDL and LDL) elevations were summarized, especially the conformational changes of lipoprotein particles. Due to the incapability of the current assays and highly heterogeneous of lipoprotein particles, the function of lipoprotein in cholesterol transport remains elusive with regard to many important questions, such as how the lipoprotein particle assembles and how the assembly modulates the neutral lipids dynamic exchanges at the molecular level. Cryo-EM coupled with MD simulations have revealed several important mechanisms of CETP-mediated lipid exchange and metabolism with all-atom detail [89, 95]. Further researches could pay more attention to simultaneously monitor the dynamic structural change of lipoproteins and the dynamic mechanism of lipid transfer, especially the internal motivation of physical mechanism during the process of lipid transport.



Project supported by the National Natural Science Foundation of China under Grant No. 11374237, 11504287, 11774279 and 11774280, Fundamental Research Funds for the Central Universities (xjj2017029), China Postdoctoral Science Foundation (2017 M613147) and Shaanxi Province Postdoctoral Science Foundation (2017).


Conflict of interest

The authors have declared that no competing interests exist.


  1. 1. Yamashita T et al. Anti-inflammatory and immune-modulatory therapies for preventing atherosclerotic cardiovascular disease. Journal of Cardiology. 2015;66(1):1
  2. 2. Chistiakov DA et al. Mechanisms of foam cell formation in atherosclerosis. Journal of Molecular Medicine. 2017;95(11):1153-1165
  3. 3. Lusis AJ, Pajukanta P. A treasure trove for lipoprotein biology. Nature Genetics. 2008;40(2):129-130
  4. 4. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. Nutrition Reviews. 1967;276(1):34
  5. 5. Kannel WB et al. Risk factors in coronary HEART disease. An evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study. Annals of Internal Medicine. 1964;61(1):888-899
  6. 6. Glomset JA et al. Role of plasma lecithin: Cholesterol acyltransferase in the metabolism of high density lipoproteins. Journal of Lipid Research. 1966;7(5):638
  7. 7. Kingwell BA et al. HDL-targeted therapies: Progress, failures and future. Nature Reviews. Drug Discovery. 2014;13(6):445-464
  8. 8. Tatami R et al. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation. 1981;64(6):1174-1184
  9. 9. Superko HR, Nejedly M, Garrett B. Small LDL and its clinical importance as a new CAD risk factor: A female case study. Progress in Cardiovascular Nursing. 2002;17(4):167-173
  10. 10. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoprotein proteins I. Preliminary in vitro and in vivo observations. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism. 1972;260(2):212-221
  11. 11. Eisenberg S, Bilheimer DW, Levy RI. The metabolism of very low density lipoprotein proteins: II. Studies on the transfer of apoproteins between plasma lipoproteins. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism. 1972;280(1):94-104
  12. 12. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233
  13. 13. Parks JS, Chung S, Shelness GS. Hepatic ABC transporters and triglyceride metabolism. Current Opinion in Lipidology. 2012;23(3):196
  14. 14. Rousset X et al. Lecithin: Cholesterol acyltransferase: From biochemistry to role in cardiovascular disease. Current Opinion in Endocrinology, Diabetes, and Obesity. 2009;16(2):163
  15. 15. Hoekstra M, Van Berkel TJ, Van Eck M. Scavenger receptor BI: A multi-purpose player in cholesterol and steroid metabolism. World Journal of Gastroenterology: WJG. 2010;16(47):5916
  16. 16. Martinez LO et al. Ectopic β-chain of ATP synthase is an apolipoprotein AI receptor in hepatic HDL endocytosis. Nature. 2003;421(6918):75-79
  17. 17. Fielding CJ, Fielding P. Molecular physiology of reverse cholesterol transport. Journal of Lipid Research. 1995;36(2):211-228
  18. 18. Schaefer EJ, Anthanont P, Asztalos BF. High-density lipoprotein metabolism, composition, function, and deficiency. Current Opinion in Lipidology. 2014;25(3):194-199
  19. 19. Barter PJ et al. Cholesteryl ester transfer protein – A novel target for raising HDL and inhibiting atherosclerosis. Arteriosclerosis Thrombosis & Vascular Biology. 2003;23(2):160-167
  20. 20. Qiu X et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nature Structural & Molecular Biology. 2007;14(2):106
  21. 21. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. Journal of Clinical Investigation. 1990;85(4):1234
  22. 22. Rubin EM et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353(6341):265-267
  23. 23. Tangirala RK et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 1999;100(17):1816-1822
  24. 24. Rosenson RS et al. Translation of high-density lipoprotein function into clinical practice. Circulation. 2013;128(11):1256-1267
  25. 25. Rader DJ et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. Journal of Lipid Research. 2009;50(Supplement):S189-S194
  26. 26. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circulation Research. 2005;96(12):1221-1232
  27. 27. Borhani DW et al. Crystal structure of truncated human apolipoprotein AI suggests a lipid-bound conformation. Proceedings of the National Academy of Sciences. 1997;94(23):12291-12296
  28. 28. Brouillette CG et al. Structural models of human apolipoprotein AI: A critical analysis and review. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids. 2001;1531(1):4-46
  29. 29. Rogers DP et al. Structural analysis of apolipoprotein AI: Effects of amino-and carboxy-terminal deletions on the lipid-free structure. Biochemistry. 1998;37(3):945-955
  30. 30. Brouillette CG et al. Förster resonance energy transfer measurements are consistent with a helical bundle model for lipid-free apolipoprotein AI. Biochemistry. 2005;44(50):16413-16425
  31. 31. Borhani DW, Engler JA, Brouillette CG. Crystallization of truncated human apolipoprotein AI in a novel conformation. Acta Crystallographica Section D: Biological Crystallography. 1999;55(9):1578-1583
  32. 32. Mei X, Atkinson D. Crystal structure of C-terminal truncated apolipoprotein AI reveals the assembly of high density lipoprotein (HDL) by dimerization. Journal of Biological Chemistry. 2011;286(44):38570-38582
  33. 33. Chetty PS et al. Helical structure and stability in human apolipoprotein AI by hydrogen exchange and mass spectrometry. Proceedings of the National Academy of Sciences. 2009;106(45):19005-19010
  34. 34. Chetty PS et al. Apolipoprotein AI helical structure and stability in discoidal high-density lipoprotein (HDL) particles by hydrogen exchange and mass spectrometry. Proceedings of the National Academy of Sciences. 2012;109(29):11687-11692
  35. 35. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. Journal of Molecular Medicine. 2006;84(4):276
  36. 36. Ajees AA et al. Crystal structure of human apolipoprotein AI: Insights into its protective effect against cardiovascular diseases. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(7):2126-2131
  37. 37. Jonas A, Kézdy KE, Wald JH. Defined apolipoprotein A-I conformations in reconstituted high density lipoprotein discs. Journal of Biological Chemistry. 1989;264(9):4818-4824
  38. 38. Jonas A et al. Reaction of discoidal complexes of apolipoprotein A-I and various phosphatidylcholines with lecithin cholesterol acyltransferase. Interfacial effects. Journal of Biological Chemistry. 1987;262(9):3969-3974
  39. 39. Jonas A et al. Apolipoprotein A-I structure and lipid properties in homogeneous, reconstituted spherical and discoidal high density lipoproteins. Journal of Biological Chemistry. 1990;265(36):22123-22129
  40. 40. Segrest JP et al. A detailed molecular belt model for apolipoprotein AI in discoidal high density lipoprotein. Journal of Biological Chemistry. 1999;274(45):31755-31758
  41. 41. Koppaka V et al. The structure of human lipoprotein AI evidence for the “belt” model. Journal of Biological Chemistry. 1999;274(21):14541-14544
  42. 42. Mishra VK et al. Association of a model class A (apolipoprotein) amphipathic α helical peptide with lipid high resolution NMR studies of peptide lipid discoidal complexes. Journal of Biological Chemistry. 2006;281(10):6511-6519
  43. 43. Bhat S et al. Conformational adaptation of apolipoprotein AI to discretely sized phospholipid complexes. Biochemistry. 2007;46(26):7811-7821
  44. 44. Martin DD et al. Apolipoprotein AI assumes a “looped belt” conformation on reconstituted high density lipoprotein. Journal of Biological Chemistry. 2006;281(29):20418-20426
  45. 45. Wu Z et al. The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nature Structural & Molecular Biology. 2007;14(9):861-868
  46. 46. Chetty PS et al. Comparison of apoA-I helical structure and stability in discoidal and spherical HDL particles by HX and mass spectrometry. Journal of Lipid Research. 2013;54(6):1589-1597
  47. 47. Wu Z et al. Double superhelix model of high density lipoprotein. Journal of Biological Chemistry. 2009;284(52):36605-36619
  48. 48. Jones MK et al. Assessment of the validity of the double superhelix model for reconstituted high density lipoproteins A combined computational-experimental approach. Journal of Biological Chemistry. 2010;285(52):41161-41171
  49. 49. Zhang L et al. Morphology and structure of lipoproteins revealed by an optimized negative-staining protocol of electron microscopy. Journal of Lipid Research. 2011;52(1):175-184
  50. 50. Murray SC et al. Direct measurement of the structure of reconstituted high-density lipoproteins by Cryo-EM. Biophysical Journal. 2016;110(4):810-816
  51. 51. Bibow S et al. Solution structure of discoidal high-density lipoprotein particles with a shortened apolipoprotein AI. Nature Structural & Molecular Biology. 2017;24(2):187-193
  52. 52. Segrest J et al. Surface density-induced pleating of a lipid monolayer drives nascent high-density lipoprotein assembly. Structure. 2015;23(7):1214-1226
  53. 53. Silva RGD et al. Structure of apolipoprotein AI in spherical high density lipoproteins of different sizes. Proceedings of the National Academy of Sciences. 2008;105(34):12176-12181
  54. 54. Gursky O. Crystal structure of Δ (185-243) apoA-I suggests a mechanistic framework for the protein adaptation to the changing lipid load in good cholesterol: From flatland to sphereland via double belt, belt buckle, double hairpin and trefoil/tetrafoil. Journal of Molecular Biology. 2013;425(1):1-16
  55. 55. Wu Z et al. The low resolution structure of ApoA1 in spherical high density lipoprotein revealed by small angle neutron scattering. Journal of Biological Chemistry. 2011;286(14):12495-12508
  56. 56. Huang R et al. Apolipoprotein AI structural organization in high-density lipoproteins isolated from human plasma. Nature Structural & Molecular Biology. 2011;18(4):416-422
  57. 57. Segrest JP, Jones MK, Catte A. MD simulations suggest important surface differences between reconstituted and circulating spherical HDL. Journal of Lipid Research. 2013;54(10):2718-2732
  58. 58. Goldstein JL, Brown MS. Low-density lipoprotein pathway and its relation to atherosclerosis. Annual Review of Biochemistry. 1977;46:897-930
  59. 59. Vainio S, Ikonen E. Macrophage cholesterol transport: A critical player in foam cell formation. Annals of Medicine. 2003;35(3):146-155
  60. 60. Born GV. New determinants of the uptake of atherogenic plasma proteins by arteries. Basic Research in Cardiology. 1994;89(Suppl 1(1)):103
  61. 61. Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B48-and B100-containing lipoproteins in atherogenesis. Current Opinion in Lipidology. 2002;13(5):461-470
  62. 62. Glass CK, Witztum JL. Atherosclerosis: The road ahead. Cell. 2001;104(4):503-516
  63. 63. Kruth H. Macrophage foam cells and atherosclerosis. Frontiers in Bioscience: A Journal and Virtual Library. 2001;6:D429-D455
  64. 64. Ross R. The pathogenesis of atherosclerosis (second of two parts). The New England Journal of Medicine. 1976;295:420-425
  65. 65. Qiao J-H et al. Role of macrophage colony-stimulating factor in atherosclerosis: Studies of osteopetrotic mice. The American Journal of Pathology. 1997;150(5):1687
  66. 66. Liu LK et al. Mulberry anthocyanin extracts inhibit LDL oxidation and macrophage-derived foam cell formation induced by oxidative LDL. Journal of Food Science. 2008;73(6)
  67. 67. Prassl R, Laggner P. Molecular structure of low density lipoprotein: Current status and future challenges. European Biophysics Journal. 2008;38(2):145
  68. 68. Chapman MJ, Guérin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. European Heart Journal. 1998;19:A24-A30
  69. 69. Prassl R. Human low density lipoprotein: The mystery of core lipid packing. Journal of Lipid Research. 2011;52(2):187-188
  70. 70. Galeano NF et al. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: A potential mechanism for increased atherogenicity. Journal of Lipid Research. 1998;39(6):1263-1273
  71. 71. Lundkatz S et al. Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: Implication for LDL receptor interaction. Biochemistry. 1998;37(37):12867-12874
  72. 72. Deckelbaum RJ et al. Thermal transitions in human plasma low density lipoproteins. Science. 1975;190(4212):392-394
  73. 73. Pownall HJ et al. Effect of saturated and polyunsaturated fat diets on the composition and structure of human low density lipoproteins. Atherosclerosis. 1980;36(3):299-314
  74. 74. Pregetter M et al. Microphase separation in low density lipoproteins. Journal of Biological Chemistry. 1999:274
  75. 75. Baumstark MW et al. Structure of human low-density lipoprotein subfractions determined by X-ray small-angle scattering. Biochimica et Biophysica Acta. 1990;1037(1):48-57
  76. 76. Spin JM, Atkinson D. Cryoelectron microscopy of low density lipoprotein in vitreous ice. Biophysical Journal. 1995;68(5):2115-2123
  77. 77. Orlova EV et al. Three-dimensional structure of low density lipoproteins by electron cryomicroscopy. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(15):8420-8425
  78. 78. Sherman MB et al. Structure of triglyceride-rich human low-density lipoproteins according to cryoelectron microscopy. Biochemistry. 2003;42(50):14988-14993
  79. 79. Segrest JP et al. Structure of apolipoprotein B-100 in low density lipoproteins. Journal of Lipid Research. 2001;42(9):1346
  80. 80. Kumar V et al. Three-dimensional cryoEM reconstruction of native LDL particles to 16Å resolution at physiological body temperature. PLoS One. 2011;6(5):e18841
  81. 81. Vauhkonen M, Somerharju P. Parinaroyl and pyrenyl phospholipids as probes for the lipid surface layer of human low density lipoproteins. Biochimica et Biophysica Acta. 1989;984(1):81-87
  82. 82. Ren G et al. Model of human low-density lipoprotein and bound receptor based on CryoEM. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(3):1059-1064
  83. 83. Morehouse LA et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand white rabbits. Journal of Lipid Research. 2007;48(6):1263-1272
  84. 84. Rennings AJ, Stalenhoef A. JTT-705: Is there still future for a CETP inhibitor after torcetrapib? Expert Opinion on Investigational Drugs. 2008;17(10):1589
  85. 85. Xie L et al. Drug discovery using chemical systems biology: Identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Computational Biology. 2009;5(5):e1000387
  86. 86. Clark RW et al. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. Journal of Lipid Research. 2006;47(3):537-552
  87. 87. Ranalletta M et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. Journal of Lipid Research. 2010;51(9):2739-2752
  88. 88. Nicholls SJ et al. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. American Heart Journal. 2015;170(6):1061-1069
  89. 89. Zhang L et al. Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nature Chemical Biology. 2012;8(4):342-349
  90. 90. Zhang L et al. An optimized negative-staining protocol of electron microscopy for apoE4 center dot POPC lipoprotein. Journal of Lipid Research. 2010;51(5):1228-1236
  91. 91. Cilpakarhu G, Jauhiainen M, Riekkola ML. Atomistic MD simulation reveals the mechanism by which CETP penetrates into HDL enabling lipid transfer from HDL to CETP. Journal of Lipid Research. 2015;56(1):98-108
  92. 92. Lei D et al. Structural features of cholesteryl ester transfer protein: A molecular dynamics simulation study. Proteins Structure Function & Bioinformatics. 2013;81(3):415-425
  93. 93. Lei D et al. Insights into the tunnel mechanism of cholesteryl Ester transfer protein through all-atom molecular dynamics simulations. Journal of Biological Chemistry. 2016;291(27):14034-14044
  94. 94. Lauer ME et al. Cholesteryl ester transfer between lipoproteins does not require a ternary tunnel complex with CETP. Journal of Structural Biology. 2016;194(2):191-198
  95. 95. Zhang M et al. HDL surface lipids mediate CETP binding as revealed by electron microscopy and molecular dynamics simulation. Scientific Reports. 2015;5:8741

Written By

Zhiwei Yang, Dongxiao Hao, Yizhuo Che, Lei Zhang and Shengli Zhang

Submitted: February 7th, 2018 Reviewed: February 27th, 2018 Published: August 8th, 2018